Data Monitoring Committee Recommends Continuation of APOLLO Phase 3 Clinical Trial of Patisiran for Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)

ByConnor Hodde

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that the Data Monitoring Committee (DMC) for the Phase 3 APOLLO study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN) met on October 7, 2016 and recommended continuation of the trial without modification.

Read the entire article here.

Similar Posts

Serum retinol-binding protein-induced endothelial inflammation is mediated through the activation of toll-like receptor 4

ByConnor Hodde

“Retinol-binding protein 4 (RBP4) is a novel adipokine (adipose-derived cytokine) that is clinically associated with obesity, insulin resistance, type 2 diabetes (T2DM), and cardiovascular disease. In addition, patients with proliferative diabetic retinopathy (DR) have increased serum RBP4 levels compared to diabetic patients with mild or no retinopathy, which raises the possibility that RBP4 is somehow…

NIH-Industry Collaboration Advances Gene-Agnostic Treatment for Retinal Disease

ByConnor Hodde

A new study from the National Institutes of Health (NIH) has shown promising results for reserpine—a medication originally approved in 1955 for high blood pressure—as a potential treatment to prevent vision loss caused by inherited blinding diseases such as retinitis pigmentosa. In preclinical studies, reserpine protected retinal neurons essential for vision, particularly in females. Unlike…

Adolescents with Diabetes Experiencing Decrease in Retinopathy

ByConnor Hodde

A long-term study from Australia has claimed that there has been a significant reduction in the number of cases of retinopathy among young patients with type 1 diabetes who have had intensive glycaemic control therapy. http://www.diabetes.co.uk/news/2011/Oct/adolescents-with-diabetes-experiencing-decrease-in-retinopathy-95087803.html

Preparation of anti-tumor nanoparticles using tiger milk mushroom

ByConnor Hodde

A recent breakthrough from Hong Kong Polytechnic University uses tiger milk mushroom to prepare anti-tumor nanoparticles is bringing us one step closer. A natural compound found in mushrooms may hold the key to a new class of cancer drugs. In Tiger Milk mushrooms from Africa, Dr Wong Ka-hing, Associate Director of the Food Safety and…

Repair of Rhodopsin mRNA by Spliceosome-Mediated RNA Trans-Splicing: A New Approach for Autosomal Dominant Retinitis Pigmentosa

ByConnor Hodde

The promising clinical results obtained for ocular gene therapy in recent years have paved the way for gene supplementation to treat recessively inherited forms of retinal degeneration.  We used spliceosome-mediated RNA trans-splicing as a strategy for repairing the transcript of the rhodopsin gene, the gene most frequently mutated in autosomal dominant retinitis pigmentosa (RP).  Retinitis…

FDA approves first retinal implant for rare eye disease

ByConnor Hodde

The U.S. Food and Drug Administration has approved the first artificial retina, an implanted device that replicates some of the function of the retina, helping to restore vision to people blinded with a rare genetic disorder. The device is intended to replace the function of light-sensing cells in the retina destroyed by retinitis pigmentosa, an…